Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    Oxfenicine

    go.drugbank.com/drugs/DB04291
    Experimental

    Oxfenicine in an inhibitor of myocardial metabolism of nonesterified fatty acids (NEFA).

  2. Drug

    EC-0652

    go.drugbank.com/drugs/DB15340
    Experimental

    EC-0652 is under investigation in clinical trial NCT02202447 (Phase 1 of EC1169 In Patients With Recurrent MCRPC).

  3. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  4. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  5. Drug

    Influenza A virus A/California/7/2009 (H1N1)-like hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14382
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14384
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14386
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  8. Drug

    Influenza B virus B/Texas/6/2011 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14387
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza A virus A/Victoria/361/2011 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB14395
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza B virus B/Wisconsin/1/2010 live (attenuated) antigen

    go.drugbank.com/drugs/DB14396
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.